While psychedelic studies have largely excluded patients deemed to be higher risk, Scott T. Aaronson, a psychiatrist at the Institute for Advanced Diagnostics and Treatment in the Sheppard Pratt Health System, has made them a focus of his group’s psilocybin research. In 2021, Aaronson and colleagues initiated the first study of psilocybin for patients with bipolar II disorder in fifteen patients…
